Oculis Holding AG (OCS) Return on Capital Employed (2023 - 2026)

Oculis Holding AG's (OCS) quarterly Return on Capital Employed came in at 31.8% in Q1 2026, up 1648.0% year-on-year from 1.82% in Q1 2025, and up 10.2% quarter-over-quarter from 35.41% in Q4 2025.

Oculis Holding AG (OCS) Return on Capital Employed (2023 - 2026) Analysis & Trends

Oculis Holding AG's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 31.8% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 1648.0% year-over-year to 31.8% in Q1 2026; TTM through Mar 2026 was 31.8%, a 1648.0% increase from a year earlier, with the FY2025 full-year figure at 59.21%, up 4254.0% from the prior year.
  • Return on Capital Employed climbed to 31.8% in Q1 2026 per OCS's latest filing, from 35.41% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 31.8% in Q1 2026 and bottomed at 76.62% in Q4 2023.
  • The 4-year median for Return on Capital Employed is 48.28% (2025), against an average of 52.66%.
  • Across the five-year window, Return on Capital Employed surged 808 bps in 2024 and surged 3312 bps in 2025, its largest moves.
  • Year by year, Return on Capital Employed stood at 76.62% in 2023, then increased by 11 bps to 68.53% in 2024, then surged by 48 bps to 35.41% in 2025, then rose by 10 bps to 31.8% in 2026.
  • Per Business Quant, the three latest OCS Return on Capital Employed figures stand at 31.8% (Q1 2026), 35.41% (Q4 2025), and 38.87% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -31.80%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 10.46%
4 NuCana 279.75 Bn 279.75 Bn - -68.47%
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 21.10%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 10.19%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -68.84%
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn 20.34%

Historic Data

Download Data
DateValue
Mar 31, 2026 -31.80%
Dec 31, 2025 -35.41%
Sep 30, 2025 -38.87%
Jun 30, 2025 -37.43%
Mar 31, 2025 -48.28%
Dec 31, 2024 -68.53%
Sep 30, 2024 -47.94%
Jun 30, 2024 -66.13%
Mar 31, 2024 -57.80%
Dec 31, 2023 -76.62%
Sep 30, 2023 -70.48%